Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS), a partner of the ZIKAlliance consortium, announced that it has entered into a collaborative research agreement with Chongqing Zhifei Biological Products Stock Co., Ltd. (Zhifei) for the clinical studies and commercialization of a recombinant Zika virus subunit vaccine developed by IPS-CAS.
5th April 2017 •
comment
The key message from this study is that the large uncertainty around the risk estimate needs to be further investigated because of a) the possible existence of co-factors that are yet to be validated, b) the assumptions that the authors needed to make in the absence of good data for the proportion of women who were infected during pregnancy.
10th March 2017 •
comment
3rd March 2017 •
comment
15th International Dengue Course and ZIKAlliance WP1 meeting to be held in Cuba next August
by ZIKAlliance
2nd March 2017 •
comment
Submit an article
We welcome contributions from members. Please submit an article for review by our editorial team.
Upload nowCategories
- Antibiotics (2)
- Asia (4)
- Child Health (1)
- Childhood (1)
- Clinical trials (5)
- Communications (Mesh) (1)
- Community Engagement (3)
- Coronavirus (24)
- COVID-19 (WEPHREN Resources) (14)
- CRF (2)
- Data Management (1)
- Data Management and Statistics (2)
- Disease-specific Guidance (3)
- Epidemics (Mesh) (4)
- Ethics and Informed Consent (1)
- Funding (5)
- Global Health (2)
- Global Health Research Ethics (3)
- Health Inequality (2)
- Health Policy and Management (4)
- Infectious diseases (17)
- Maternal/Fetal health during pregnancy (1)
- Operational/Governance (19)
- Pandemic preparedness (13)
- Pneumonia (3)
- Press Release (2)
- Publications (3)
- Regulations and Guidelines (5)
- Reports (2)
- Resources (11)
- Sampling (2)
- Statistics (1)
- Study Protocols (5)
- Training (9)
- Trial Design (7)
- Trial Management (5)
- Trial Operations (4)
- Vaccine safety (1)
- Workshops (3)